Insights
News from Altio, and practical notes on the platform, security, and where AI in regulated life sciences is heading.
News · Collaboration
ELIQUENT brings deep pharmacovigilance expertise from years of work inside regulated environments. Altio brings AI built specifically for life sciences. It is early days, and we will share more as the work takes shape.
News · Open Altio
Open Altio is live: twenty years of FDA adverse event reports, cleaned and deduplicated, free to use, with the code and every cleaning rule open on GitHub.
Platform · Security
An automated audit checks our own code, the third-party code we rely on, the running application, our cloud configuration and our AI features. This is what that process does, in plain terms.
Thought leadership · Strategy
Knowledge in R&D leaves when people do. Altio builds the longitudinal record that survives them, and a decision intelligence layer that answers questions across every module it runs.
Platform · Architecture
Our patent-pending core encodes what a domain requires once, then extends it, so every new domain inherits the same traceable record instead of a rebuild.
Platform · Architecture
Traceability is not a feature bolted on after the fact. At TRL 4, we can show the working, not just the output, because the architecture was built for it from the start.
Platform · Security
Access control, encryption, and threat modeling built from first principles, an embedded-systems approach applied to a platform that cannot afford to get this wrong.
Thought leadership · Regulatory
Every regulated decision stays with a qualified human expert. That is why Altio's risk profile is minimal/limited risk, not classified as high-risk under the EU AI Act.
Thought leadership · Strategy
Most point tools get rebuilt for every new domain. COG is built once at the core and extended instead, and that is the bet we are making.
Platform · Security
AI agents do the discovery and drafting, deterministic code does the deciding, and every gate between them fails closed.